foxg1

2022 Impact Report

2022 Impact Report

2022 Research Highlights (see details below)

  • Breakthrough gene therapy results showing rescue of FOXG1 brain structure, behavior, memory and cognition symptoms in animal models

  • Positive results on initial compound drug screens to identify molecules to increase FOXG1 levels; now moving forward to larger screens

  • Never-before understanding of FOXG1 biology uncovered from six FOXG1 patient human cell lines and mouse models 

  • Successful testing of guide RNAs to increase FOXG1 expression with a CRISPRa Cas-9 system

  • Discovered ASO sequences (antisense gene therapy) to modulate FOXG1 expression; testing initiated with Creyon Bio  

  • FOXG1 data package presented to several biotech companies with high interest


ONCE UPON A GENE - EPISODE 163 - How Far We've Come - with Nicole Johnson

Effie Parks talks to the co-founder of the FOXG1 Research Foundation, Nicole Johnson in this episode of Once Upon a Gene. Nicole shares the FOXG1 Research Foundation journey marking five years, and shares tips on how to throw a successful conference for scientists, clinicians and parents from all over the world

FOXG1 Research Foundation to Pioneer a Machine Learning Approach to Accelerate Rare Disease Research with Support From the Chan Zuckerberg Initiative

The parent-led FOXG1 Research Foundation (FRF) announced today a nearly $500k grant from the Chan Zuckerberg Initiative (CZI) to revolutionize the ability for patient-led advocacy groups to use machine learning to help accelerate rare disease drug development.

The First FOXG1 Scientists Symposium - A Recap.

The first FOXG1 symposium was a tremendous success in bringing together scientists from around the world who are interested in research around FOXG1 to collaborate with one another to find a cure. Scientists from Japan, Australia, Italy, the UK, the US, and more, presented and held deep-diving sessions to discuss what we know and what we need to know to drive research for FOXG1 syndrome.